Neurodegenerative Diseases
Managing disease to improve patients’ lives
Merck Serono is committed to bringing hope to people suffering from neurodegenerative diseases. We have a long-term commitment
to the development of innovative treatments to help manage neurological disorders such as Multiple Sclerosis (MS) and Parkinson’s
disease (PD).
Through groundbreaking science and patient-friendly drug delivery systems, we help patients with neurodegenerative diseases
to live fuller and more satisfying lives. Our portfolio of currently marketed products includes Rebif®, which is approved
for the treatment of relapsing-remitting multiple sclerosis in over 80 countries worldwide.
In addition, Merck Serono conducts extensive research in the area of neurodegenerative diseases in order to offer new therapeutic
options to patients with high unmet medical needs. We currently have several late-stage projects in our R&D pipeline addressing unmet needs in MS and PD.
More about:
| Disclaimer |
|
This section gives an overview of our Company's activities in neurodegenerative diseases. The information may refer to pharmaceutical products, therapeutics or indications not yet registered or approved in a given country. US Residents should consult the EMD Serono, Inc. for information on products approved for sale in the United States of America. |
